A detailed history of Pro Share Advisors LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 43,056 shares of LXRX stock, worth $30,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,056
Previous 34,725 23.99%
Holding current value
$30,569
Previous $58,000 15.52%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.51 - $2.39 $12,579 - $19,911
8,331 Added 23.99%
43,056 $67,000
Q2 2024

Aug 13, 2024

BUY
$1.54 - $2.28 $1,507 - $2,232
979 Added 2.9%
34,725 $58,000
Q1 2024

May 08, 2024

BUY
$1.3 - $3.58 $3,593 - $9,895
2,764 Added 8.92%
33,746 $80,000
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.53 $2,933 - $4,487
2,933 Added 10.46%
30,982 $47,000
Q3 2023

Nov 13, 2023

BUY
$1.06 - $2.33 $3,958 - $8,700
3,734 Added 15.36%
28,049 $30,000
Q2 2023

Aug 10, 2023

BUY
$2.15 - $3.49 $3,072 - $4,987
1,429 Added 6.24%
24,315 $55,000
Q1 2023

May 11, 2023

SELL
$1.99 - $2.68 $6,841 - $9,213
-3,438 Reduced 13.06%
22,886 $55,000
Q4 2022

Feb 02, 2023

BUY
$1.8 - $2.56 $3,058 - $4,349
1,699 Added 6.9%
26,324 $50,000
Q3 2022

Nov 04, 2022

BUY
$1.94 - $3.43 $9,298 - $16,439
4,793 Added 24.17%
24,625 $59,000
Q2 2022

Aug 01, 2022

SELL
$1.31 - $2.69 $11,400 - $23,411
-8,703 Reduced 30.5%
19,832 $37,000
Q1 2022

May 10, 2022

SELL
$1.95 - $3.89 $15,057 - $30,038
-7,722 Reduced 21.3%
28,535 $60,000
Q4 2021

Feb 08, 2022

BUY
$3.81 - $6.16 $138,139 - $223,343
36,257 New
36,257 $143,000
Q3 2021

Nov 12, 2021

SELL
$3.38 - $5.35 $59,528 - $94,224
-17,612 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$4.12 - $5.87 $17,810 - $25,376
4,323 Added 32.53%
17,612 $81,000
Q1 2021

May 14, 2021

BUY
$3.45 - $9.09 $45,847 - $120,797
13,289 New
13,289 $78,000
Q4 2020

Feb 09, 2021

SELL
$1.05 - $3.67 $23,437 - $81,918
-22,321 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$1.44 - $2.1 $548 - $800
-381 Reduced 1.68%
22,321 $32,000
Q2 2020

Aug 03, 2020

BUY
$1.75 - $2.3 $9,850 - $12,946
5,629 Added 32.97%
22,702 $45,000
Q1 2020

May 15, 2020

SELL
$1.8 - $4.28 $20,761 - $49,365
-11,534 Reduced 40.32%
17,073 $33,000
Q4 2019

Feb 12, 2020

SELL
$3.16 - $5.15 $15,449 - $25,178
-4,889 Reduced 14.6%
28,607 $119,000
Q3 2019

Nov 12, 2019

SELL
$1.2 - $6.66 $2,522 - $13,999
-2,102 Reduced 5.9%
33,496 $101,000
Q2 2019

Aug 13, 2019

SELL
$5.35 - $7.11 $27,204 - $36,154
-5,085 Reduced 12.5%
35,598 $224,000
Q1 2019

May 15, 2019

BUY
$4.36 - $7.94 $1,050 - $1,913
241 Added 0.6%
40,683 $226,000
Q4 2018

Feb 14, 2019

SELL
$6.15 - $10.51 $49,335 - $84,311
-8,022 Reduced 16.55%
40,442 $269,000
Q3 2018

Nov 14, 2018

SELL
$10.32 - $13.06 $17,574 - $22,241
-1,703 Reduced 3.39%
48,464 $517,000
Q2 2018

Aug 13, 2018

SELL
$7.8 - $13.69 $32,448 - $56,950
-4,160 Reduced 7.66%
50,167 $602,000
Q1 2018

May 14, 2018

SELL
$7.86 - $11.39 $70,378 - $101,986
-8,954 Reduced 14.15%
54,327 $466,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $7,463 - $10,450
851 Added 1.36%
63,281 $625,000
Q3 2017

Nov 13, 2017

BUY
$12.17 - $16.3 $56,030 - $75,045
4,604 Added 7.96%
62,430 $767,000
Q2 2017

Aug 11, 2017

BUY
N/A
57,826
57,826 $951,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.